

ANNUAL REPORT
2012 • 2013

SOLUTIONS ARE IN THE GENES

www.genomequebec.com

GenomeQuébec

WHICH WOMEN ARE MORE AT RISK OF DEVELOPING BREAST CANCER?

Development of a decision-making support tool that will help extend the benefits of the current screening program to those women most at risk for breast cancer.

To learn more, visit genomequebec.com

Jacques Simard, Université Laval and
Centre hospitalier universitaire de Québec

CHOOSING THE BEST MEDICATION FOR EPILEPSY

Development of a pharmacogenomic tool for the more accurate diagnosis of various forms of epilepsy, particularly those that are drug resistant. Improved diagnoses mean better quality of life for patients.

To learn more, visit genomequebec.com

Patrick Cossette, Centre hospitalier universitaire
de l'Université de Montréal (CHUM)

BETTER TREATMENT OF CARDIOVASCULAR DISEASES

Development of pharmacogenomic tests to render more effective the management of patients with cardiovascular diseases. Among their many benefits, these decision-support tools, developed for health professionals, would improve treatments while reducing negative effects.

To learn more, visit genomequebec.com

Jean-Claude Tardif, Montreal Heart Institute, Université de Montréal

MANAGING BLOOD CANCERS



Breakthrough improvement in the effectiveness of immunotherapy used to treat chemo-resistant cancer by reducing sixfold the rejection rate and developing a targeted lymphocyte transplant strategy.

To learn more, visit genomequebec.com



Claude Perreault, Hôpital Maisonneuve-Rosemont and
the Institute for Research in Immunology and
Cancer of Université de Montréal

Read about the four other Genome Canada competition winners on page 5.

VISION

Genomics is a driving force critical to Québec's future.

TABLE OF CONTENTS

THANK YOU TO OUR PARTNERS

Enseignement supérieur, Recherche, Science et Technologie
Québec

GenomeCanada

Corporate information

For more information, please contact the Public Affairs and Communications Department at 514-398-0668 or Louise Thibault by e-mail at lthibault@genomequebec.com

Head office Génome Québec
630 René-Lévesque Blvd. West, Suite 2660
Montréal, Québec H3B 1S6
514-398-0668 • Fax 514-398-0883
gqinfo@genomequebec.com
www.genomequebec.com

Auditors–KPMG LLP
600 de Maisonneuve Blvd. West, Suite 1500
Montréal, Québec H3A 0A3
www.kpmg.ca

Legal adviser–M^e^ Jean Brunet
Stein Monast, S.E.N.C.R.L • 70 Dalhousie Street, Suite 300
Québec, Québec G1K 4B2

Genome Canada
150 Metcalfe Street, Suite 2100, Ottawa, Ontario K2P 1P1
www.genomecanada.ca

Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie
1035 De La Chevrotière Street, Québec, Québec G1R 5A5
www.mesrst.gouv.qc.ca

McGill University and Génome Québec Innovation Centre
740 Doctor Penfield Ave., Montréal, Québec H3A 1A4
514-398-7211 • Fax 514-398-1790
infoservices@genomequebec.com

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank
305 St-Vallier Street, Chicoutimi, Québec G7H 5H6
514-398-7211
infoservices@genomequebec.com

ISBN 978-2-9811988-3-9
Legal deposit–Bibliothèque et Archives nationales du Québec,
Legal deposit–Library and Archives Canada, 2013

Martin Godbout,
Chairman of the board

"Our organization must implement the necessary measures to make discoveries and applications accessible to users. Our goal is to make sure key partners grasp the importance and seize the opportunities afforded by genomics, so it may continue to be a central component of Québec's strategic policies."

MESSAGE FROM THE CHAIRMAN OF THE BOARD

This year, more than ever, Génome Québec's actions were destined for success. Thanks to the excellent work of Québec researchers, along with access to top-notch research infrastructures at the McGill University and Génome Québec Innovation Centre and support from academic, industry and government partners, 2012-2013 has been a phenomenal year for genomic research here in Québec.

My vision since taking the helm of the Génome Québec board in June 2011 has been to make genomics accessible to society. This year, transforming this vision into a reality meant providing researchers with proactive support in preparing their funding requests for the Génome Canada-CIHR competition in personalized health by moving closer to the medical community, foundations, patient groups and, ultimately, to citizens.

For example, we played the role of an intermediary, connecting philanthropic foundations with Génome Québec-funded research groups. We did this by taking part in a major fundraising campaign for the Leukodystrophies Foundation and developing a partnership with the Grand défi Pierre Lavoie, which will result in specific research activities in coming years. Through our involvement, genomics is helping these organizations reach their goals of identifying and validating genes responsible for genetic diseases, so that the development process of new drugs can move along more quickly.

IMPROVING ACCESS TO DISCOVERIES AND APPLICATIONS

The year 2013-2014 will be critical for us, as we continue to develop our partnerships. Our pivotal role as facilitator and hub of the research and innovation life sciences ecosystem has been validated: we must support researchers in securing funds, both at the national and international levels. More specifically, Génome Québec counts on building stronger ties with industry through the new Genomic Applications Partnership Program (GAPP).

It is vital to ensure that discoveries emerging from genomics are accessible to the public and that applications are promptly integrated into sectors where they are needed: human health, agri-food, the environment and forestry. The potential of genomics must be fully exploited for the benefits of users and the public.

I wish to take this opportunity to thank the members of the board, as well as the Québec and Canadian governments, for helping to make genomics one of the pillars of our economic and social development. I also extend heartfelt thanks to our President and CEO, Marc LePage, for his efforts in achieving Génome Québec's objectives this year.

On behalf of the members of the board and as its chair, I would also like to congratulate Québec's award-winning researchers for their exceptional work and performance at the Genome Canada/CIHR competition. The bright and promising future awaiting genomics in Québec society is ultimately in their hands.

Génome Québec

MESSAGE FROM THE PRESIDENT AND CEO

To ensure the superior performance of our researchers in Genome Canada's new Personalized Health Competition, we needed to provide them with the best possible support. To do so, we decided a change in approach was warranted. This meant reaching out to clinicians, patient groups, regulatory bodies and health agencies to build ties with them and harmonize their respective interests and objectives, at the same time meeting the requirements of the national competition.

Our new approach proved to be on target, since Québec-based research teams garnered 60 percent of the national funding available. This all-time record clearly demonstrates Québec's leadership in personalized medicine.

Of course, this success would not have been possible without the backing of the Québec government. In these difficult, unpredictable economic times, it had the foresight and courage to lend us its unwavering support, as evidenced by the $34.2 million in funding it allocated to our organization. This sum, combined with investments from the federal government and private partners, amounted to a total of close to $100 million, which will be used to develop personalized health care in Québec.

McGILL UNIVERSITY AND GÉNOME QUÉBEC INNOVATION CENTRE

A few years ago, we made the informed decision to combine both the expertise and infrastructures of the McGill University and Génome Québec Innovation Centre, a move that has allowed us to boost the quality of our analytical services and reduce our costs per unit. It proved to be a wise decision indeed, since we are now serving over 800 research teams, both here in Québec and around the world.

Having the capacity to provide services to the entire scientific community has always been a priority for us, in keeping with the principle of universal access to genomics. In our view, the Innovation Centre is a prized asset that broadens the international influence of genomics, of research and ultimately of Québec. For this reason, it should be considered a valuable calling card to be fully leveraged in the promotion of our researchers abroad.

OUR FOCUS AND STRATEGIES FOR THE FUTURE

The challenges that lie ahead represent amazing growth opportunities for Génome Québec, in particular as regards the integration of genomic applications into our healthcare systems. To that end, we will be launching a clinical genomic platform in Québec, a Canadian first. This groundbreaking initiative falls right in line with the major investments now being made in the modernization of mega-hospitals. It will also give Québec a distinct advantage on the international stage.

In addition to our work in human health, we have our sights set on the key sectors of forestry and the environment. Our natural resources play a vital role in Québec's economic development and contribute to the well-being of our communities. We hold firmly that genomics is an important pillar of sustainable development and must be recognized as such.

Yet another major issue represents an important challenge for the future: that of striking the right balance between basic research and applied research. Our experience has taught us that only by recognizing the two as inseparable can we hope to position Québec as a world-class leader in research and innovation.

I take this opportunity, in closing, to thank our management team for its leadership and vision when meeting the many challenges of 2012-2013. Our success is also the result of the support and dedication of our staff, because, as we all know, achieving any goal requires teamwork above all.

Marc LePage,
President and CEO

"At the beginning of the year, the team at Génome Québec identified three broad priorities. The first was to succeed in the Genomics and Personalized Health Competition launched by Genome Canada and the Canadian Institutes of Health Research. The second was to secure financing and the third was to strengthen the positioning of the McGill University and Génome Québec Innovation Centre.

I take personal satisfaction in the fact that it's 'mission accomplished' on all fronts. Here are some of the year's highlights."

SCIENTIFIC ACTIVITY REPORT

Catalina López Correa, Vice President, Scientific Affairs

"These projects will generate nearly $100 million in investments in the field of genomics in Québec and contribute to the province's social and economic growth."

The life sciences sector, one of Québec's main driving forces, has always been an important focal point for Génome Québec and, as such, we are intent on playing a leading role in its expansion. In 2012-2013, the Scientific Affairs team was hard at work preparing researchers for the Genomics and Personalized Health Competition launched by Genome Canada and the Canadian Institutes of Health and Research. Our goal was to secure top standing for the province. With Québec research teams garnering 60 percent of the federal funding available, we can confidently say that objective was met.

In 2012-2013, the Genomics and Personalized Health Competition consumed much of our department's efforts and energy. Our job was to develop and implement a strategy to support research teams participating in the competition. This involved a change in practice from our traditional approach of offering researchers timely assistance to providing ongoing support.

The shift in approach was made all the more challenging by the fact that Genome Canada's criteria represented a whole new way of doing things in research. For the first time, one of the main selection criteria was a project's ability to provide deliverables with tangible socioeconomic benefits within 4 to 5 years. In other words, researchers were asked to propose research projects with a clear path to benefits for patients and our healthcare systems. Given the competition's strong focus on socioeconomic benefits, our support strategy entailed providing our management teams and researchers with access to pertinent external resources, such as consultants and other experts, in order to help them prepare competitive applications.


14 LA PRESSE AFFAIRES — LA PRESSE MONTRÉAL JEUDI 18 AVRIL 2013

LA PRESSE PORTFOLIO GÉNOMIQUE

Le Québec excelle en génomique

Les scientifiques québécois possèdent-ils le gène de la recherche en génomique? Ils ont raflé 60 % des sommes offertes dans le cadre du concours sur la génomique et la santé personnalisée, organisé par Génome Canada et les Instituts de recherche en santé du Canada.

Les huit lauréats québécois, choisis par un jury indépendant, ont chacun reçu entre 5 et 10 millions de dollars de Génome Canada, Génome Québec et les Instituts de recherche en santé du Canada pour poursuivre leurs travaux. Rencontre avec ces pionniers de la médecine de demain.

UN DOSSIER DE **GUY PAQUIN**, COLLABORATION SPÉCIALE

Thanks to systematic, careful preparation, the Québec scientific community fared extremely well at meeting the requirements of the Genome Canada competition: 8 large-scale research projects (out of 17 overall in Canada) won top honours. The project budgets range from $5.1 million to $13.5 million, a significant contribution to research in Québec. These projects will help advance the development of treatments and therapies in several different areas, such as oncology, screening, prenatal diagnostics, cardiovascular diseases, inflammatory diseases and neurology. Spearheaded by some of Québec's top minds, the projects will be conducted in three leading universities: Université de Montréal (5 projects), Université Laval (2 projects) and McGill University (1 project).

Working in partnership with Genome Canada, we also continued to develop the strategic positioning of four key sectors–forestry, mining and the environment, aquaculture and agri-food–through workshops with sector stakeholders. The purpose of these workshops was to facilitate interaction with end users and industry partners in these areas.

In addition this year, our team worked on strengthening its management practices through various initiatives, such as the implementation of a new project management database.

In 2013 and beyond, the Scientific Affairs team will be focusing its energy on the proactive management of research projects based on the specific needs and expected deliverables of each project. As funding agencies increasingly look to applied research and call for measurable socioeconomic benefits by the end of the funding period, we will continue to rely on the support strategy we developed this year; it has proved reliable and extremely effective. It will also be important to continue supporting our researchers down the line, as their research results are integrated into our healthcare systems, and to promote the benefits of their work among the general public.

NEW APPROACH TO BRAIN CANCER

Development and implementation of a diagnostic test for clinical trials to stratify pediatric patients with brain cancer. This unprecedented approach will finally lead to better targeted, thus more effective, treatments.

To learn more, visit genomequebec.com

Nada Jabado, Research Institute of the McGill University Health Centre

CONQUER INFLAMMATORY BOWEL DISEASES

Development of tests enabling doctors to match the right drug with the right patient. Patients avoid having to take ineffective (often costly) medications and this, in turn, means a better quality of life for them.

To learn more, visit genomequebec.com

John David Rioux, Montreal Heart Institute, Université de Montréal

SAFER PRENATAL SCREENING

Conduct of an independent study to compare the performance and usefulness of new genomic prenatal screening methods using a simple blood test, which could replace amniocentesis.

To learn more, visit genomequebec.com

François Rousseau, Université Laval and Centre hospitalier universitaire de Québec

REVERSE LEUKEMIA

Increase of the survival rate of patients with acute myeloid leukemia by selecting treatment based on the genetic makeup of their leukemia cells.

To learn more, visit genomequebec.com

Guy Sauvageau, Institute for Research in Immunology and Cancer of Université de Montréal

Génome Québec

ACTIVITY REPORT FOR THE TECHNOLOGY CENTRES

Daniel Tessier,
Vice President,
Technology Centres

"Our main goal is to promote the competitiveness and expertise of Québec and Canadian genomic researchers internationally through the quality of their findings and the number of scientific articles they publish.

One of our challenges now is to translate these research results into clinical applications."

Daniel C. Tessier

Génome Québec runs and operates two large technology centres whose role is to support major research initiatives in genomics and provide the scientific community with cutting-edge services. This year, a new vice presidency was created to oversee the centres and align their objectives with Génome Québec's corporate mission.

In 2012-2013, the activities of the technology centres were organized around:

- Optimizing their access strategies and cutting-edge technological equipment
- Harmonizing their standardized management processes

McGILL UNIVERSITY AND GÉNOME QUÉBEC INNOVATION CENTRE

As a result of the Innovation Centre's ongoing involvement in the genotyping of samples from COGS (Collaborative Oncological Gene-Environment Study) consortium, based at Cambridge University in the U.K., new international partnerships were developed and a series of articles published in the journal *Nature Genetics* made headlines in Québec and around the world.

This year, the Innovation Centre proceeded with the migration of its IT infrastructure to enhance its high-throughput analysis capabilities, an improvement that has increased its storage capacity as well. In an effort to optimize and standardize its operations, it also automated several of its work procedures, for greater quality and efficiency.

Furthermore, the Centre welcomed four new researchers from McGill University. Along with their research teams, they will be contributing to the development and implementation of new technologies and applications.

On the competition front, Scientific Director Mark Lathrop and Bioinformatics Director Guillaume Bourque received generous support from the Canadian Institutes of Health Research (CIHR) and Génome Québec to continue their ground-breaking research in the field of epigenetics. This funding will go toward studying how environmental factors can alter DNA expression and have long-term effects on human health.

FINANCIAL RESULTS THAT SPEAK VOLUMES

It was a banner year for the Centre, as its revenues reached the record sum of $11.9 million, a 2 percent increase over last year. The Centre's cumulative revenues for the past 10 years now stand at nearly $100 million.

In addition, the Centre, which serves over 800 research teams, continues to enjoy an enviable level of client satisfaction, since 80 percent of new users are referred by current users.

REVENUES BY GEOGRAPHIC REGION



GÉNOME QUÉBEC AND CENTRE HOSPITALIER AFFILIÉ UNIVERSITAIRE RÉGIONAL DE CHICOUTIMI BIOBANK

The Biobank is continuing to provide CARTaGENE the support it needs to pursue its growth by optimizing the quality of its sample storage processes.

CARTaGENE

In addition to its technology centres, Génome Québec financially supports CARTaGENE.

This year marked the launch of the second wave of recruitment aiming to increase the current study cohort by 17,000 participants. Recruitment is still underway and so far response rates have been excellent. Recruitment is expected to end in 2015.



Génome Québec

ACTIVITY REPORT FROM PUBLIC AFFAIRS AND COMMUNICATIONS

Marie-Kym Brisson, Vice President, Public Affairs and Communications

"Génome Québec must be recognized as the Québec leader in genomics and personalized medicine. We want the public and all eventual end users to really understand the huge potential of this research field, which is poised to offer our community solutions in health and sustainable development."

Genomics is at a turning point in its history. Its derived socioeconomic benefits and potential for applications are growing strong, a trend that will continue its upward climb in coming years.

Now is the time for us to put out a clear and powerful message to the public and our partners about the value of genomics to ensure its successful integration in society. Here at Public Affairs and Communications, we have our work cut out for us, since our job is to translate into direct, user-friendly language the benefits of genomics and show–not just tell–the public the many positive spinoffs stemming from investments in genomics.

To ensure the effectiveness of our actions, in fall 2012, we launched what would serve as our guidepost for future activities: the first public opinion poll on genomics among Quebecers. The poll confirmed that the public supports genomic research and our governments' decision to invest in this field, especially when it comes to genomics and health.

With this information in hand, we were able to establish an action plan to help us better reach out to the public. We were proactive in our approach and will continue to forge ahead along the same path, since our strategy generated results almost immediately.

Key messages identified:

1. Genomics is about people: They want explanations on the latest tangible benefits derived from genomics.
2. Genomics can help solve real social problems, whether in health or the environment.
3. Genomics is one of our strengths and a source of collective pride.



Our first initiative was to create an interactive Website to serve as a platform for exchanges on genomics. We also cultivated a presence on social media–Facebook, Twitter and LinkedIn–allowing us to share all year long the latest news and important announcements in genomics.



To learn more, visit genomequebec.com

THE WEBSITE IN NUMBERS*

News items: 64
Information bulletins: 10 (7 on health)
Increase in number of hits vs. March 2012: 32.94%

*March 31st, 2013



To learn more, visit facebook.com/genomeQc

SOCIAL MEDIA IN NUMBERS*

Facebook: more than 900 fans
Twitter: more than 150 followers
LinkedIn: 374 followers

*March 31st, 2013

ACTIVITY REPORT FROM PUBLIC AFFAIRS AND COMMUNICATIONS (continued)

After the extraordinary performance of Québec researchers in the Genome Canada/CIHR competition, we developed a specific strategy to generate maximum impact among the public:



A new visual identity that sends a powerful, concise message.

Proactive media relations campaigns–for example, a special Portfolio issue in La Presse.

SUCCESS OF THE "SOLUTIONS ARE IN OUR GENES" VIDEO–A FEW STATS

Website: 1,490 hits
YouTube: 1,795 views
Facebook: Viral 15,631, Organic 941, 66 likes

To learn more, visit genomequebec.com

An emotionally engaging video that prominently features patients and researchers.

SUPPORTING OUR SCIENTISTS

Moreover, to make sure our spokespersons are fully equipped to speak to the media–and ultimately to the public–we suggested that our management team and some of the researchers funded under the genomics and Personalized Health Competition follow a media training program with a public relations firm.

We were also proactive in approaching the media regarding the series of articles published in Nature Genetics in March 2013. The series, co-authored by Jacques Simard of Université Laval and CHU de Québec, presented findings of the international COGS (Collaborative Oncological Gene-Environment Study) consortium based in Cambridge, U.K. The news item was featured in some 10 articles in the Québec press, mentioned over 20 times and discussed during television and radio interviews.

One of the main challenges soon to face Génome Québec is how to position genomics as a strategic priority for Québec's socioeconomic development.

FINANCIAL ACTIVITY REPORT

Génome Québec receives most of its financial support from Genome Canada and the Québec ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie for the funding of research projects and the operation of its technology centres.

As of March 31, 2013, our research portfolio included 42 genomics projects, and two technology centres are currently in operation. Génome Québec invested $38.8 million during the 2012-2013 fiscal year. This amount, combined with the $14 million invested by other partners, brings our overall injection of funds to $52.8 million.

Business volume generated by research projects during the fiscal year amounts to $34.3 million. This year, Génome Québec managed projects under these competitions: LSARP (large-scale applied research project competition), ABC (applied genomics research in bioproducts or crops), Génome Québec Human Health, Québec Vert and recruitment programs. The budget for projects still underway totals $201 million.

For the year ended on March 31, 2013, sales from our technology centre totalled $12.1 million, down 5% compared to last year due to the closing of the NIML Centre during the previous fiscal year. The technology centres posted an excess of revenue over expenses of $1.2 million. Since last year, $2.6 million has been earmarked for the development of the Innovation Centre's scientific strategic plan as of March 31, 2013.

General and administrative expenses, communications and outreach costs and committee expenses totalled $3.1 million this year, or 5.9% of total expenses, compared to $3 million (adjusted for non-recurring expenditures), or 5.9% last year. This slight rise reflects the cost control plan for general and administrative expenses. Investment revenue reached $953,000, for a return of 2.2%.

During the fiscal year, the excess of revenue over expenses totalled $0.9 million. Of this surplus, non-designated net assets rose by $323,000, for a sum of $3.2 million. Net assets totalling $500,000 remain in the contingency and technological development funds, and a sum of $287,000 has been set aside for activities related to the commercialization of research findings.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.

Marc LePage
President and CEO
Génome Québec

Claude Lamarre
Vice President, Finance
Génome Québec

GÉNOME QUÉBEC AND ACTIVITIES 2012-2013
Total Investment of $52.8M



GÉNOME QUÉBEC AND PARTNERS



Génome Québec

STATEMENTS OF FINANCIAL POSITION

The Statement of Financial Position as at March 31, 2013, March 31, 2012, and April 1, 2011 and the Statement of Operations for the years ended March 31, 2013 and 2012 that follow are provided as illustrative summaries only and are not intended to replace the full financial statements of Génome Québec. These full financial statements were audited and reported on June 18, 2013 by KPMG LLP, Chartered Professional Accountants.

STATEMENTS OF FINANCIAL POSITION
MARCH 31, 2013, MARCH 31, 2012 AND APRIL 1, 2011

	MARCH 31, 2013	MARCH 31, 2012	APRIL 1, 2011
ASSETS			
Current assets:			
Cash and cash equivalents	$4,572,079	$10,482,241	$1,236,547
Short-term investments	17,414,409	15,577,054	2,392,893
Accounts receivable and work in progress	2,111,289	2,492,734	2,609,172
Contribution receivable	—	—	14,000
Advances to genomic research projects	1,416,999	4,584,756	—
Inventories	765,660	709,846	605,707
Prepaid expenses	294,068	463,095	290,349
	26,574,504	34,309,726	7,148,668
Long-term investments	18,401,474	23,886,467	29,305,338
Capital assets	502,464	710,232	1,612,674
	$45,478,442	$58,906,425	$38,066,680
LIABILITIES AND NET ASSETS			
Current liabilities:			
Accounts payable and accrued liabilities	$2,995,490	$2,302,456	$3,337,538
Deferred revenues	143,974	418,267	180,606
Due to genomic research projects	—	—	1,884,740
Contributions to be reimbursed	—	—	2,448,194
Obligations related to an agreement	1,280,000	640,000	—
	4,419,464	3,360,723	7,851,078
Obligations related to an agreement	1,297,501	919,221	—
Deferred contributions:			
Future expenses	35,234,538	50,501,524	25,607,372
Capital assets	347,416	479,631	1,129,177
	35,581,954	50,981,155	26,736,549
Net assets:			
Unrestricted	3,237,660	2,914,725	2,181,214
Restricted–Invested in capital assets	155,048	230,601	483,497
Restricted–Technology investment and contingency fund	500,000	500,000	814,342
Restricted–Research Projects	286,815	—	—
	4,179,523	3,645,326	3,479,053
	$45,478,442	$58,906,425	$38,066,680

STATEMENTS OF OPERATIONS
YEARS ENDED MARCH 31, 2013 AND 2012

	2013	2012
Revenues:		
Amortization of deferred contributions related to expenses	$27,871,962	$21,895,838
Amortization of deferred contributions related to capital assets	282,951	767,407
Investment income	953,018	914,255
Revenues from technology centres	12,115,820	12,777,166
Other revenues	160,536	110,162
	41,384,287	36,464,828
Expenses:		
Genomic research projects	20,264,698	14,341,834
Technology centre operational costs	15,790,975	15,411,328
Projects–Technology investment and contingency fund	732,238	926,028
General and administrative	2,631,400	2,512,071
Communications and public outreach	381,582	272,960
Committees	28,219	82,061
Strategic initiatives	225,000	688,473
Depreciation of capital assets	282,951	767,407
Depreciation of restricted capital assets	134,747	377,172
	40,471,810	35,379,334
Excess of revenues over expenses	$912,477	$1,085,494

Génome Québec

MEMBERS OF THE BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES

BOARD OF DIRECTORS

Chairman of the Board
Martin Godbout, PhD

Vice Chairman of the Board
Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma

Secretary Treasurer of the Board
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

BOARD MEMBERS

Hélène Desmarais, C.M., LL.D.
CEO and Chair of the Board of Administration, Centre d'entreprises et d'innovation de Montréal

Thomas J. Hudson, MD
President and Scientific Director
Ontario Institute for Cancer Research

Raymond Langlois, CPA, CA
Vice President, Portfolio Manager
RBC Dominion Securities

Marc LePage
President and CEO
Génome Québec

Monique Létourneau,
ICD.D, CFA, MSc
President, Défistratège

Rémi Quirion,
O.C., PhD, FRSC, CQ
Chief Scientist of Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President
Research and Innovation
Director - Bureau for Internationalization and Partnership in Research (BIPER)
Université Laval

OBSERVERS

Jean Belzile
Assistant Deputy Minister
Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie

Pierre Meulien, PhD
President and CEO
Genome Canada

EXECUTIVE COMMITTEE

Chairman of the Committee
Martin Godbout, PhD

Secretary of the Committee
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma

Marc LePage
President and CEO
Génome Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President
Research and Innovation
Director - Bureau for Internationalization and Partnership in Research (BIPER)
Université Laval

MANAGEMENT COMMITTEE

Marc LePage
President and CEO

Marie-Kym Brisson
Vice President, Public Affairs and Communications

Claude Lamarre
Vice President, Finance

Catalina López Correa
Vice President, Scientific Affairs

Daniel Tessier
Vice President, Technology Centres

GOVERNANCE COMMITTEE

Chairman of the Committee
Martin Godbout, PhD

Secretary of the Committee
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma

Marc LePage
President and CEO
Génome Québec

AUDIT AND INVESTMENT COMMITTEES

Acting Chair of the Committee
Monique Létourneau,
ICD.D, CFA, MSc
President, Défistratège

Daniel Bouthillier, PhD, MBA
President and CEO, Kaneq Pharma

Raymond Langlois, CPA, CA
Vice President, Portfolio Manager
RBC Dominion Securities

HUMAN RESOURCES COMMITTEE

Chairman of the Committee
Martin Godbout, PhD

Secretary of the Committee
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Marc LePage
President and CEO
Génome Québec

Rémi Quirion, O.C., PhD, FRSC, CQ
Chief Scientist of Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President Research and Innovation
Director - Bureau for Internationalization and Partnership in Research (BIPER)
Université Laval

NOMINATION COMMITTEE

President of the Committee
Martin Godbout, PhD

Secretary of the Committee
Jean Brunet, Attorney
Managing Partner, Stein Monast L.L.P.

Daniel Bouthillier, PhD, MBA
President and Chair of the Board of Administration
Kaneq Pharma

Marc LePage
President and CEO
Génome Québec

Paule Têtu, F. Eng., MSc
Associate to the Vice President
Research and Innovation
Director - Bureau for Internationalization and Partnership in Research (BIPER)
Université Laval

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Chairman of the Committee
Camille Limoges, PhD

Jo Bury, PhD, MBA
VIB

Chuck Hasel, PhD, MBA
Hasel Consulting

Antoine Kremer, PhD
The French National Institute for Agricultural Research

Matthew Mailman, PhD
Janssen Research & Developement

Mark McCarthy, PhD
Wellcome Trust, Oxford

Teri Manolio, MD, PhD
National Institutes of Health (NIH)

GÉNOME QUÉBEC EMPLOYEES

Anne-Marie Alarco
Vicky Arsenault
Steve Arsenault
François-Marie Bacot
Yolande Bastien
Alexandre Belisle
Line Benguerel
Carolina Bocanegra
Julie Boudreau
Mathieu Bourgey
Guillaume Bourque
Geneviève Bourret
Marie-Kym Brisson
Sébastien Brunet
François Cantin
Valérie Catudal
Christine Cellier
Sébastien Chaffre
Patrice Charbonneau Larose
Marie-Paule Choquette
Cristina Ciurli
Catherine Côté
Geneviève Dancausse
Philippe Daoust
Burak Demirtas
Haig Djambazian
Geneviève DonPierre
Nathalie Émond
Joëlle Fontaine
Hélène Fournier
Rosalie Fréchette
Geneviève Geneau
Philippe Gingras Gélinas
Claire Goguen
Daniel Guertin
Isabelle Guillet
Alexandru Guja
Nathalie Hamel
Nathaly Hébert
Cecilia Hernandez
Louis Dumond Joseph
Éva Kammer
Danielle Kemmer
François Korbuly
Audrey Anne Kustec
Sylvie LaBoissière
Marc-André Labonté
Claude Lamarre
François Lefebvre
Fabienne Lefebvre
Pierre Lepage
Marc LePage
Darie Lessard
Louis Létourneau
Ginette Levasseur
Gary Leveque
Catalina López Correa
Stéphanie Lord-Fontaine
Christine Martens
François Massé
Aurélie Masurel
Terrance McQuilkin
Marc Michaud
Jana Mickova
Alexandre Montpetit
Thuong Ngo
Frédérick Robidoux
Sharen Sophie Roland
Jonathan Roux
Johanna Sandoval
Étienne Sdicu
Alfredo Staffa
Janick St-Cyr
Daniel Tessier
Louise Thibault
Belisle Tir
Thay Leng Tony Tir
Vincent Trudel
Julie Vallée
Tu Linh Van
Annie Verville
Daniel Vincent
Hoai-Thu Vo
Patrick Willett
Hao Fan Yam
Chung-Yan Yuen
Corine Zotti

LARGE-SCALE PROJECT OUTCOMES

MARCH 31, 2013	Number of persons employed in the 4th Quarter 2011-2012	Number of scientists trained in the 4th Quarter 2011-2012	Number of publications accepted or submitted	Number of conferences as speaker	Number of declarations of inventions or patents	Project starting date
ABC COMPETITION						
Thomas Bureau - McGill • VEGI (crop improvement)	5	10	2	3	0	October 2009
Adrian Tsang - Concordia • Genozymes (Bioproducts and Bioprocesses Development)	20.3	6	9	8	8	October 2009
Peter Facchini - UAlberta/Vincent Martin - Concordia • Phytometasyn (Synthetic Biosystems for the Production of High Value Plant Metabolites)	32	23	23	30	2	October 2009
Richard Gold - McGill • Valgen (Value Addition Through Genomics)	33.05	3.5	6	6	0	October 2009
TOTAL	**90.35**	**42.5**	**40**	**47**	**10**	
RECRUITMENT COMPETITIONS						
DIRECTOR CARTAGENE						
Philip Awadalla - CHU Ste-Justine • CARTaGENE	4	4	17	28	0	January 2010
HUMAN HEALTH						
Mike Tyers - UdM • Biological networks in human health	19	12	19	13	1	April 2011
Mark Lathrop - McGill • Medical Genomics	8	4	0	5	0	April 2011
TOTAL	**31**	**20**	**36**	**46**	**1**	
2010 LARGE-SCALE APPLIED RESEARCH PROJECT COMPETITION						
John MacKay - ULaval /Jörg Bohlman - UBC • SMarTForest (Sustainable Forestry)	26	16	21	43	0	July 2011
B. Franz Lang/Mohamed Hijri - UdM • GenoRem (Decontaminating Soils)	35	35	10	38	0	July 2011
TOTAL	**61**	**51**	**31**	**81**	**0**	
ENTREPRENEURSHIP EDUCATION IN GENOMICS (EEG) PROGRAM						
Denis J. Garand - ULaval • BEST in Genomics! (maximizing knowledge transfer)	6.2	1	1	12	0	October 2011
TOTAL	**6.2**	**1**	**1**	**12**	**0**	
GQ HEALTH COMPETITION						
Gregor Andelfinger - CHU Ste-Justine • Congenital Heart Disease	4.5	2.5	0	0	0	October 2010
Guy A. Rouleau - CHUM • Bipolar Disorder	7	0	2	0	0	October 2010
Guy Sauvageau - IRIC • Acute Myeloid Leukemia	13.26	3	2	3	1	October 2010
John H. White - McGill • Tuberculosis	5.5	3	4	7	0	October 2010
Ken Dewar - McGill • Digestive problems	1	0.4	1	5	0	October 2010
Mark Basik - Lady Davis Institute • Breast Cancer	8.5	4.5	2	1	0	October 2010
Michael Hallet - McGill • Breast Cancer	3.67	0.75	7	4	0	October 2010
Alain Moreau - CHU Ste-Justine • Diagnostic Tool for Pediatric Scoliosis	11.6	6	2	9	0	October 2010
Michel G. Bergeron - ULaval • Rapid Diagnostic Tests	12	0.5	0	7	1	October 2010
Maryam Tabrizian - McGill • Portative Biosensors	6.3	6	6	10	0	October 2010
Paul Goodyer - CUSM • Cell therapy of cystinosis	4	1	1	3	0	October 2010
Pavel Hamet - CHUM • Type 2 Diabetes	10.9	3.05	4	15	3	October 2010
Gordon Shore/Michel L. Tremblay - McGill • Cancer Therapy	6.4	1.5	0	2	0	October 2010
TOTAL	**94.63**	**32.2**	**31**	**66**	**5**	
GQ PILOT PROJECT COMPETITION						
Jamie Engert - CUSM • Heart Disease	3	0	0	0	0	October 2010
Julie St-Pierre - McGill • Breast Cancer	1	2	1	1	0	October 2010
Pierre Drapeau/Edor Kabashi - UdM • New Therapeutic Approaches	3	2	3	12	1	October 2010
Roger C. Levesque - ULaval • Budwork EcoGenomics	3.4	1	3	15	0	October 2010
Sarah Kimmins - McGill • Infertility	0.55	1.75	1	6	0	October 2010
Zoha Kibar - CHU Ste-Justine • Neural Tube Defects	0.75	1	0	0	0	October 2010
TOTAL	**11.7**	**7.75**	**8**	**34**	**1**	
QUÉBEC VERT COMPETITION						
François Belzile - ULaval • GreenSNPs (Environmental Genomics)	1	0	2	3	0	January 2012
Connie Lovejoy - ULaval • CATG (Genomics for the Arctic Environment)	3	2	2	3	0	January 2012
Vincent Martin - Concordia • PAYGE (Reducing Fossil Fuel Dependency)	1	0	0	0	0	January 2012
TOTAL	**5**	**2**	**4**	**6**	**0**	
2012 LARGE-SCALE APPLIED RESEARCH PROJECT COMPETITION • PERSONALIZED HEALTH						
Claude Perreault - HMR • Immunotherapy (Cancer)			Startup			April 2013
Patrick Cossette - CHUM • Epilepsy			Startup			April 2013
Guy Sauvageau - UdeMontréal • Leucegene GC (Acute myeloid leukemia)			Startup			April 2013
Francois Rousseau - ULaval • PEGASUS (Prenatal aneuploidy screening using maternal blood)			Startup			April 2013
Jacques Simard - ULaval • Breast cancer (Prevention and early detection)			Startup			April 2013
John Rioux - ICM • iGenomed (Inflammatory bowel diseases)			Startup			April 2013
Jean-Claude Tardif - ICM • Cardiovascular diseases (Targeted therapeutics)			Startup			April 2013
Nada Jabado - Research Institute of the MUHC • (Pediatric brain cancer)			Startup			April 2013
2012 BIOINFORMATICS AND AND COMPUTATIONAL BIOLOGY COMPETITION						
Jérome Waldispuhl - McGill • Science games in genomics			Startup			July 2013
Mathieu Blanchette - McGill • PIATEA			Startup			July 2013
COMPETITION TOTAL (projects in progess)	**299.88**	**156.45**	**151**	**292**	**17**	

ASSESSMENT OF COMPLETED PROJECTS

MARCH 31, 2013	Number of persons employed in person-years	Number of scientists trained in person-years	Number of publications accepted or submitted	Number of conferences as speaker	Number of declarations of inventions or patents	Project duration
COMPETITIONS I & II, HEALTH						
Michel G. Bergeron - CHUQ • Theranostic Technologies (Diagnostic Tests to identify microbes causing infections)	118	25	25	58	11	3.25 years
Deming Xu - Privé • Chemogenomics (New Therapeutic Treatments for Life-Threatening Fungal Infections)	32	2	8	4	1	3 years
Thomas J. Hudson - McGill • ARCTIC (Colorectal Cancer)	42	6	19	15	9	3.25 years
Franz Lang - UdM • Protist EST (Evolution of Eukaryotic cells and Corresponding Genes)	49	21	20	18	0	3.5 years
Bussey/Michnick - McGill • Model Organisms (Genetic Interaction in Eukaryotic cells)	20	4	18	55	0	4 years
John J.M. Bergeron - McGill • Proteomics (Function and Structure of Genes and Proteins)	174	67	42	125	7	4 years
Fernand Labrie - ULaval • Atlas (Profiles of Steroid Action)	347	120	49	29	2	5 years
Bartha Maria Knoppers - McGill • GE³LS (Genomics and Society)	38	20	83	153	0	4 years
Fathey Sarhan - UQAM • (Abiotic Stress Québec (Improve Agricultural Productivity)	82	28	11	17	0	4 years
Thomas J. Hudson - McGill • Regulatory Genetics (Identification of Regulatory Polymorphisms in the Human Genome)	117	27	16	51	6	4 years
Rafick-Pierre Sékaly - UdM • S2K (Immune Response)	194	79	17	150	6	4 years
Mario Fillion - McGill • IGWH (Women's Health)	36	5	1	10	4	3 years
Sherif Abou Elela - USherbrooke • MoNa (genome wide analysis of gene function)	51	8	6	9	2	3 years
Adrian Tsang - Concordia • Fungal Enzymes (Environmental Remediation)	167	69	16	22	8	3 years
Benoît Coulombe - UdM • Regulatory Networks (Decoding Genetic Information)	189	63	15	111	0	3.5 years
John MacKay - ULaval • Arborea I (Health of Trees)	98	31	23	63	2	3.5 years
Thomas J. Hudson - McGill • HapMap (Genetic Research)	34	2	14	87	1	3 years
Emil Skamene - McGill • Congenic Mice (Dissect Complex Traits Relevant to Human Health)	60	13	2	11	3	4.25 years
Guy Rouleau - UdM • Ionic Channels (Hereditary Neurological Disorder)	40	5	0	16	3	4.25 years
Terry Roemer - Private • Candida albicans (Antifungal Drug Discovery)	51	0	2	3	3	3 years
Barry Posner/Rob Sladek - McGill • Type 2 Diabetes	5	0	25	35	6	5.5 years
Bartha Maria Knoppers - McGill • GPH (Genomics and Public Health)	5	4	22	47	0	January 2006
COMPETITION III, INTERNATIONAL CONSORTIUM INITIATIVE, PRIVAC, TECHNOLOGY DEVELOPMENT COMPETITION						
Sherif Abou Elela - USherbrooke • FAESI (alternative splicing)	101.48	10.82	11	28	3	5.25 years
Ken Dewar - McGill • Vervet Monkey (Neuro-development and Neurological Degradation)	18.3	2	3	4	0	4.75 years
Tomi M. Pastinen - McGill • GRID (Gene Regulators)	213	51.5	84	42	2	4.5 years
Guy A. Rouleau - UdM • S2D (Brain Diseases)	86.03	12	14	41	1	5 years
Jean-Claude Tardif - ICM • Pharmacogenomics (Cardiovascular Disease)	346	41	15	87	0	4 years
John MacKay - Ulaval • Arborea II (Improve Productivity of Forest Products)	186	66.6	49	95	0	5 years
Bartha Maria Knoppers/Thomas J. Hudson - McGill • P³G/CaG (Population Genomics)	33.5	24	35	54	0	3 years
Daniel Lamarre/Sylvain Meloche - IRIC • RNA Platform (New Targeted Therapies for Cancer)	16.84	0	0	3	0	2 years
Rafick-Pierre Sékaly - UdM • NIML Platform (Vaccines and Immune Therapeutics)	18	3	4	5	2	2 years
Michel G. Bergeron - CHUQ • GPOCT (Infectiology)	45	2	9	18	1	2.25 years
Michael Phillips/Jean-Claude Tardif - ICM • Via-PGX (Cardiovascular Pharmacogenomics)	17.5	3.6	4	44	0	2.5 years
Maryam Tabrizian - McGill • DevTab (Biomarker Discovery and Validation)	35.3	15.21	34	13	0	2 years
Rafick-Pierre Sékaly/Ryan Brinkman - UdM-BCCA • DevSek (Immune System)	6	1	2	4	0	2 years
TOTAL COMPLETED PROJECTS	**3,072**	**832**	**698**	**1,527**	**83**	



630 René-Lévesque Blvd. West, Suite 2660
Montréal, Québec H3B 1S6
Phone: 514-398-0668 • Fax: 514-398-0883
gqinfo@genomequebec.com • www.genomequebec.com

GenomeQuébec